Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study.
ACE-inhibitor
Hypertension
Lisinopril
Pediatrics
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
22
04
2024
accepted:
26
08
2024
revised:
24
08
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Over the last 20 years, pediatric hypertension (pHTN) prevalence in Western society has risen from 3.5 to 9% due to childhood overweight, obesity, and secondary kidney and cardiological conditions. Few studies have assessed commonly used antihypertensive medication lisinopril's (ACE-inhibitor) long-term efficacy and the long-term value of renin-angiotensin-aldosterone system (RAAS) biomarkers. This is a retrospective cohort study at Ghent University Hospital, Belgium, with 106 young patients (1-18 years) treated with lisinopril due to hypertension (HTN) and chronic kidney disease (CKD) assessed for treatment outcomes against clinical benchmarks over 10 years. Lisinopril was mainly initiated for secondary hypertension or nephroprotection (89%) due to kidney causes. A starting dose across groups was lower than 0.07 mg/kg for 48% (n = 50). HTN patients without CKD achieved systolic blood pressure below the 95th percentile within 2 years, but efficacy declined after 2.5 years. CKD patients maintained a steady response, reaching systolic targets by 40 months and showing improved diastolic control over 70 months. Proteinuria reduction had a median urine protein creatinine ratio (UPCR) to 0.57 g/g at 6 months, with a reappearance of UPCR 2 g/g creatinine after 40 months. Aldosterone breakthrough occurred from 6 months onward in all groups. Over 70 months, aldosterone and aldosterone-renin-ratio (ARR) progression significantly differ between children with and without normal kidney function. Treatment efficacy for systolic blood pressure in hypertensive patients with abnormal kidney function diminishes after 2.5 years and for proteinuria in children after 3 years, highlighting the need for dosage recalibration according to guidelines and/or the need for alternative treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Over the last 20 years, pediatric hypertension (pHTN) prevalence in Western society has risen from 3.5 to 9% due to childhood overweight, obesity, and secondary kidney and cardiological conditions. Few studies have assessed commonly used antihypertensive medication lisinopril's (ACE-inhibitor) long-term efficacy and the long-term value of renin-angiotensin-aldosterone system (RAAS) biomarkers.
METHODS
METHODS
This is a retrospective cohort study at Ghent University Hospital, Belgium, with 106 young patients (1-18 years) treated with lisinopril due to hypertension (HTN) and chronic kidney disease (CKD) assessed for treatment outcomes against clinical benchmarks over 10 years.
RESULTS
RESULTS
Lisinopril was mainly initiated for secondary hypertension or nephroprotection (89%) due to kidney causes. A starting dose across groups was lower than 0.07 mg/kg for 48% (n = 50). HTN patients without CKD achieved systolic blood pressure below the 95th percentile within 2 years, but efficacy declined after 2.5 years. CKD patients maintained a steady response, reaching systolic targets by 40 months and showing improved diastolic control over 70 months. Proteinuria reduction had a median urine protein creatinine ratio (UPCR) to 0.57 g/g at 6 months, with a reappearance of UPCR 2 g/g creatinine after 40 months. Aldosterone breakthrough occurred from 6 months onward in all groups. Over 70 months, aldosterone and aldosterone-renin-ratio (ARR) progression significantly differ between children with and without normal kidney function.
CONCLUSIONS
CONCLUSIONS
Treatment efficacy for systolic blood pressure in hypertensive patients with abnormal kidney function diminishes after 2.5 years and for proteinuria in children after 3 years, highlighting the need for dosage recalibration according to guidelines and/or the need for alternative treatments.
Identifiants
pubmed: 39466390
doi: 10.1007/s00467-024-06531-1
pii: 10.1007/s00467-024-06531-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM et al (2017) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1345–1422
doi: 10.1016/S0140-6736(17)32366-8
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al (2015) Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circ 131:e29–322
Siddiqi N, Shatat IF (2020) Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol 35:2049–2065
pubmed: 31676933
doi: 10.1007/s00467-019-04314-7
Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ (2004) Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113:475–482
pubmed: 14993537
doi: 10.1542/peds.113.3.475
Grinsell MM, Norwood VF (2009) At the bottom of the differential diagnosis list: Unusual causes of pediatric hypertension. Pediatr Nephrol 24:2137–2146
pubmed: 18320238
doi: 10.1007/s00467-008-0744-y
Ashraf M, Irshad M, Parry NA (2020) Pediatric hypertension: an updated review. Clin Hypertens 26:22
pubmed: 33292828
pmcid: 7706222
doi: 10.1186/s40885-020-00156-w
Lubrano R, Travasso E, Raggi C, Guido G, Masciangelo R, Elli M (2009) Blood pressure load, proteinuria and renal function in pre-hypertensive children. Pediatr Nephrol 24:823–831
pubmed: 19096881
doi: 10.1007/s00467-008-1077-6
Azegami T, Uchida K, Tokumura M, Mori M (2021) Blood pressure tracking from childhood to adulthood. Front Pediatr 9:785356
pubmed: 34869128
pmcid: 8634726
doi: 10.3389/fped.2021.785356
Weir MR (2007) Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther 29:1803–1824
pubmed: 18035185
doi: 10.1016/j.clinthera.2007.09.019
Weaver DJ (2019) Pediatric hypertension: review of updated guidelines. Pediatrics Rev 40:354–358
doi: 10.1542/pir.2018-0014
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576
doi: 10.1542/peds.114.S2.555
Yagi S, Akaike M, Aihara KI, Fukuda D, Ishida M, Ise T et al (2013) Pharmacology of aldosterone and the effects of mineralocorticoid receptor blockade on cardiovascular systems. Acta Cardiol Sin 29:201
pubmed: 27122708
pmcid: 4804831
ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650. https://doi.org/10.1056/NEJMoa0902066
doi: 10.1056/NEJMoa0902066
Thethi T, Kamiyama M, Kobori H (2012) The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 14:160
pubmed: 22302531
pmcid: 3337881
doi: 10.1007/s11906-012-0245-z
Neubeck M, Fliser D, Pritsch M, Weißer K, Fliser M, Nussberger J et al (1994) Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure - consequence of dose adjustment. Eur J Clin Pharmacol 46:537–543
pubmed: 7995322
doi: 10.1007/BF00196112
Hidayani T (2019) Blood pressure levels for boys by age and height percentile. https://www.nhlbi.nih.gov/files/docs/guidelines/child_tbl.pdf . Accessed 26 Jun 2024
Roelants M, Hauspie R, Hebbelinck M, Brusselaers K (2009) [Flemish growth curves 2004]. https://researchportal.vub.be/nl/publications/vlaamse-groeicurven-2004 . Accessed 17 Apr 2024
European Medicines Agency (n.d.) Needs for paediatric medicines. https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/paediatric-medicines-research-and-development/needs-paediatric-medicines . Accessed 26 Jun 2024
U.S. Food and Drug Administration (2020) New Pediatric Labeling Information Database - Detail. https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?sd=labelingdatabase&id=14 . Accessed 11 Apr 2023
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
pubmed: 19158356
pmcid: 2653687
doi: 10.1681/ASN.2008030287
Deja A, Skrzypczyk P, Nowak M, Wrońska M, Szyszka M, Ofiara A et al (2022) Evaluation of active renin concentration in a cohort of adolescents with primary hypertension. Int J Environ Res Public Health 19:5960
pubmed: 35627493
pmcid: 9141058
doi: 10.3390/ijerph19105960
Flynn JT, Ingelfinger JR, Brady TM (eds) (2023) Pediatric hypertension, 5th edn. Springer, Cham
Raes A, Malfait F, Van Aken S, France A, Donckerwolcke R, VandeWalle J (2007) Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. J Renin Angiotensin Aldosterone Syst 8:3–12
pubmed: 17487821
doi: 10.3317/jraas.2007.004
Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S (2003) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 16:795–800
pubmed: 14553956
doi: 10.1016/S0895-7061(03)00900-2
Trachtman H, Frymoyer A, Lewandowski A, Greenbaum LA, Feig DI, Gipson DS et al (2015) Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: implications for starting dose selection. Clin Pharmacol Ther 98:25–33
pubmed: 25807932
doi: 10.1002/cpt.127
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904
pubmed: 28827377
doi: 10.1542/peds.2017-1904
Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A et al (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887–1920
pubmed: 27467768
doi: 10.1097/HJH.0000000000001039
Lande MB, Batisky DL (2019) New American Academy of Pediatrics hypertension guideline. Hypertension 73:31–32
pubmed: 30571567
doi: 10.1161/HYPERTENSIONAHA.118.11819
Carr RR, Ensom MHH (2003) Drug disposition and therapy in adolescence: the effects of puberty. J Pediatr Pharmacol Ther 8:86–96
pubmed: 23300397
pmcid: 3469156
Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C et al (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719–1742
pubmed: 19625970
doi: 10.1097/HJH.0b013e32832f4f6b
Flynn JT, Alderman MH (2005) Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol 20:961–966
pubmed: 15864653
doi: 10.1007/s00467-005-1855-3
Gansevoort RT, De Zeeuw D, De Jong PE (1996) ACE inhibitors and proteinuria. Pharm World Sci 18:204–210
pubmed: 9010883
doi: 10.1007/BF00735961
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117–124
pubmed: 12531578
doi: 10.1016/S0140-6736(03)12229-5
Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F et al (2017) Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol 18:370
pubmed: 29262813
pmcid: 5738866
doi: 10.1186/s12882-017-0789-x
Stalker HP, Holland NH, Kotchen JM, Kotchen TA (1976) Plasma renin activity in healthy children. J Pediatr 89:256–258
pubmed: 940018
doi: 10.1016/S0022-3476(76)80460-X
Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B et al (2021) Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection. Hypertension 77:891–899
pubmed: 33280409
doi: 10.1161/HYPERTENSIONAHA.120.16429
Pacurari M, Kafoury R, Tchounwou PB, Ndebele K (2014) The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam 2014:13
Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3:486–492
pubmed: 17717561
doi: 10.1038/ncpneph0575
Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A et al (2011) Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 29:2484–2490
pubmed: 22025233
doi: 10.1097/HJH.0b013e32834c625c
Schaefer F, Montini G, Kang HG, VandeWalle J, Zaritsky J, Schreuder MF et al (2024) Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials 25:203
pubmed: 38509517
pmcid: 10956186
doi: 10.1186/s13063-024-08021-z
Smith DA, Beaumont K, Maurer TS, Di L (2018) Relevance of half-life in drug design. J Med Chem 61:4273–4282
pubmed: 29112446
doi: 10.1021/acs.jmedchem.7b00969
Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren IL (1989) Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. Biopharm Drug Dispos 10:397–409
pubmed: 2547465
doi: 10.1002/bdd.2510100407
Tsai T, Kroehl ME, Smith SM, Thompson AM, Dai IY, Trinkley KE (2017) Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. J Clin Hypertens 19:868
doi: 10.1111/jch.13011
Hermida RC, Ayala DE, Mojón A, Fernández JR (2010) Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 27:1629–1651
pubmed: 20854139
doi: 10.3109/07420528.2010.510230
Hermida RC, Ayala DE, Fernández JR et al (2013) Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 30:280–314
pubmed: 23077971
doi: 10.3109/07420528.2012.709448
Fu Z, Geng X, Chi K, Song C, Wu D, Liu C et al (2021) Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Ann Palliat Med 10:7428439–7427439
Sandokji I, Greenberg JH (2021) Plasma and urine biomarkers of CKD: a review of findings in the CKiD study. Semin Nephrol 41:416–426
pubmed: 34916002
pmcid: 8694618
doi: 10.1016/j.semnephrol.2021.09.003
Ateya AM, El Hakim I, Shahin SM, El Borolossy R, Kreutz R, Sabri NA (2022) Effects of ramipril on biomarkers of endothelial dysfunction and inflammation in hypertensive children on maintenance hemodialysis: the SEARCH randomized placebo-controlled trial. Hypertension 79:1856–1865
pubmed: 35686561
doi: 10.1161/HYPERTENSIONAHA.122.19312
Liu Y, Lin Y, Zhang MM, Li XH, Liu YY, Zhao J et al (2020) The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension. BMC Cardiovasc Disord 20:1–7
pmcid: 6953233
doi: 10.1186/s12872-020-01579-x